14:43 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Human sample and mouse studies identified a mAb against misfolded SOD1 that could help treat ALS harboring SOD1 mutations. Screening of memory B cells isolated from healthy elderly volunteers for...
18:15 , Dec 7, 2018 |  BC Week In Review  |  Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations. Biogen, which opted in after seeing...
20:23 , Dec 6, 2018 |  BC Extra  |  Company News

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen Inc. (NASDAQ:BIIB) exercised its option for exclusive, worldwide rights to BIIB067 (IONIS-SOD1Rx) from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) to treat amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) mutations. Biogen, which opted in after seeing...
03:30 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

SOD1 antisense oligonucleotide improves survival in ALS model

Researchers at Biogen Inc. (NASDAQ:BIIB), Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and colleagues reported data from a rat model of superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) showing that a single bolus dose of intrathecal IONIS-SOD1Rx...
07:00 , May 12, 2016 |  BC Innovations  |  Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
07:00 , Mar 24, 2016 |  BC Innovations  |  Translation in Brief

Biogen buddies up

While some players are starting to talk of "consortia fatigue," Biogen Inc. (NASDAQ:BIIB) is doubling down on its enthusiasm for the model with two new commitments to multilateral public-private partnerships (PPPs). On February 8, the...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...